Provision of cardiovascular protection by ACE inhibitors: A review of recent trials

Current Medical Research and Opinion

Volumn 20, Issue 10, 2004, Pages 1559-1569

  Bertrand, Michel E ^a,b  

^a Lille Heart Institute   (France)

^b UNIV LILLE   (France)

Author keywords

ACE inhibitors; Anti atherosclerotic properties; Cardiovascular disease; Coronary artery disease; Endothelial function; Perindopril; Randomised clinical trials; Tissue ACE

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROHORMONE; PERINDOPRIL; STATINE;

ANIMAL EXPERIMENT; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE FUNCTION; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; ISCHEMIA; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; OXIDATIVE STRESS; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HEART ARREST; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; RISK FACTORS; VASODILATION;

EID: 7644225896     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X4185     Document Type: Review

References (58)

1. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053
2. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-640
3. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme? Lancet 2003;362:755-756
4. JNC 7. Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-2572
5. Dell'Italia LJ, Rocic P, Luchesi PA. Use of tissue angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease. Curr Probl Cardiol 2002;27:4-36
6. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001;87(Suppl):25C-32C
7. Brown N, Douglas V. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-1420
8. Remme WJ, de Leeuw PW, Bootsma M, Look MP, Kruijssen DA. Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris. Am J Cardiol 1991;68:181-186
9. Remme WJ, Kruyssen DA, Look MP, Bootsma M, de Leeuw PW Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. J Am Coll Cardiol 1994;23:82-91
10. Remme WJ, Bartels GL. Anti-ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Eur Heart J 1995;16(Suppl I):87-95
11. Noll G, Wenzel RR, de Marchi S, Shaw S, Luscher TF. Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 1997;95:2286-92
12. Bartels GL, van den Heuvel FM, van Veldhuisen DJ, van der Ent M, Remme W Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Am J Cardiol 1999;83:332-336
13. Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol 2002;88:100-7
14. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998;19(Suppl J):J7-J15
15. Lerman A, Herrmann J. Endothelial function under pressure. J Am Coll Cardiol 2003;41:1759-1760
16. Widlansky ME, Gokce N, Keaney J, Vita J. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42:1149-116
17. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281-1286
18. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65
19. Zhuo J, Mendelsohn F, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002;39 (part 2):634-8
20. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-3122
21. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000;93:65-77
22. Rosenson RS. Modulating atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol 2003;26:305-311
23. Fennessy PA, Campbell JH, Mendelsohn FAO, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Pharmacol Physiol 1996;23(Suppl 1):S30-S32
24. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246-253
25. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15:316-320
26. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001;37:1565-70
27. Kishi Y, Ohta S, Kasuya N, Sakita SY, Ashikaga T, Isobe M. Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 2003;21:1347-53
28. Asmar R, et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior® Study. J Hypertens 2001;19:813-818
29. Safar ME, et al. Arterial stiffness and kidney function. Hypertension 2004;43:163-168
30. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25:474-81
31. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000;36:220-5
32. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069
33. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327: 669-77
34. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6
35. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828
36. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85
37. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
38. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178
39. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84
40. CCS-1. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-687
41. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85
42. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122
43. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041
44. Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004;35:116-121
45. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003;24:475-84
46. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
47. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
48. Fox KM. Management of coronary artery disease: implications of the EUROPA trial. Br J Cardiol 2004;11:195-204
49. Pfeffer MA, Domanski M, Rosenberg Y, Verter J, Geller N, Albert P, Hsia J, Braunwald E. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol 1998;82:25H-30H
50. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63
51. Texter M, Lees R, Pitt B. The Quinapril Ischemic Event trial (QUIET). Design and methods of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther 1993;7:273-282
52. Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560
53. Mead M. The need for 24-hour blood pressure control. Br J Cardiol 2003;10:310-4
54. Myers MG. Methods for evaluating the duration of action of once-daily antihypertensive therapy. Blood Press Monit 2003;8:161-163
55. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001;6:63-72
56. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610
57. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000;320:705-708
58. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardi-ology/American Heart Association Task Force on Practice Guidelines, http://www.acc.org/clinical/guidelines/stable/stable_clean. pdf [Accessed 3 November 2003]